Oryzon Genomics S.A. (0RDB.L) LSE
3.10
-0.02999988(-0.96%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Oryzon Genomics S.A.
Address
Sant Ferran 74
Cornellà de Llobregat, 08940
Spain
Phone
34 93 515 13 13
Website
Sector
Healthcare
Industry
Biotechnology
Employees
47
First IPO Date
December 15, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer & President | 539,000 | N/A |
| Rolando Gutierrez-Esteinou | Chief Medical Officer for CNS Programs | 0 | 1962 |
| Xavier Perpinya Ribera | Head of Internal Audit & Compliance | 0 | N/A |
| Augusto Pinel Rubio | Secretary | 0 | N/A |
| Jordi Xaus Pey | Scientific Director | 0 | N/A |
| Neus Virgili Bernado | Director of Industrial Property | 0 | N/A |
| Sonia Paloma Gutierrez Bezon | Director of Clinical Operations | 0 | N/A |
| Emili Torrell Cortada | Director of Business Development | 0 | N/A |
| Enric Rello Condomines | Chief Operating Officer & Chief Financial Officer | 0 | N/A |
Description
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
